List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6777142/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Haemodialysis-induced hypoglycaemia and glycaemic disarrays. Nature Reviews Nephrology, 2015, 11, 302-313.	4.1	122
2	Antidiabetic Agents in Patients with Chronic Kidney Disease and End-Stage Renal Disease on Dialysis: Metabolism and Clinical Practice. Current Drug Metabolism, 2011, 12, 57-69.	0.7	119
3	Effects of Lipid-Lowering Therapy with Rosuvastatin on Kidney Function and Oxidative Stress in Patients with Diabetic Nephropathy. Journal of Atherosclerosis and Thrombosis, 2011, 18, 1018-1028.	0.9	88
4	Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease. Diabetes Technology and Therapeutics, 2019, 21, 713-720.	2.4	68
5	Best Practice for Diabetic Patients on Hemodialysis 2012. Therapeutic Apheresis and Dialysis, 2015, 19, 40-66.	0.4	64
6	Oral Zinc Supplementation Reduces the Erythropoietin Responsiveness Index in Patients on Hemodialysis. Nutrients, 2015, 7, 3783-3795.	1.7	61
7	Comparison of Sustained Hemodiafiltration With Continuous Venovenous Hemodiafiltration for the Treatment of Critically III Patients With Acute Kidney Injury. Artificial Organs, 2010, 34, 331-338.	1.0	57
8	Levocarnitine Improves Cardiac Function in Hemodialysis Patients With Left Ventricular Hypertrophy: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2016, 67, 260-270.	2.1	57
9	Effect of dialyzer membrane materials on survival in chronic hemodialysis patients: Results from the annual survey of the Japanese Nationwide Dialysis Registry. PLoS ONE, 2017, 12, e0184424.	1.1	52
10	Development and validation of subtype prediction scores for the workup of primary aldosteronism. Journal of Hypertension, 2018, 36, 2269-2276.	0.3	49
11	Plasma Insulin is Removed by Hemodialysis: Evaluation of the Relation Between Plasma Insulin and Glucose by Using a Dialysate With or Without Glucose. Therapeutic Apheresis and Dialysis, 2007, 11, 280-287.	0.4	46
12	Glycated hemoglobin or glycated albumin for assessment of glycemic control in hemodialysis patients with diabetes?. Nature Clinical Practice Nephrology, 2008, 4, 482-483.	2.0	46
13	Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertension Research, 2011, 34, 268-273.	1.5	44
14	Characterization of Insulin Adsorption Behavior of Dialyzer Membranes Used in Hemodialysis. Artificial Organs, 2011, 35, 398-403.	1.0	38
15	Mineral Metabolic Abnormalities and Mortality in Dialysis Patients. Nutrients, 2013, 5, 1002-1023.	1.7	36
16	Association Between Acute Fall in Estimated Glomerular Filtration Rate After Treatment for Primary Aldosteronism and Long-Term Decline in Renal Function. Hypertension, 2019, 74, 630-638.	1.3	36
17	Relationship Between Erythropoietin Responsiveness, Insulin Resistance, and Malnutrition-Inflammation-Atherosclerosis (Mia) Syndrome in Hemodialysis Patients with Diabetes. International Journal of Artificial Organs, 2011, 34, 16-25.	0.7	34
18	Association of restless legs syndrome with oxidative stress and inflammation in patients undergoing hemodialysis. Sleep Medicine, 2015, 16, 941-948.	0.8	34

#	Article	IF	CITATIONS
19	Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial. Diabetes and Vascular Disease Research, 2018, 15, 469-472.	0.9	34
20	Evaluation of the Hemodialysis-induced Changes in Plasma Glucose and Insulin Concentrations in Diabetic Patients: Comparison Between the Hemodialysis and Non-hemodialysis Days. Therapeutic Apheresis and Dialysis, 2007, 11, 288-295.	0.4	33
21	Comparison of the antiproteinuric effects of the calcium channel blockers benidipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3–5 chronic kidney disease. Hypertension Research, 2009, 32, 270-275.	1.5	33
22	High-Performance Membrane Dialyzers and Mortality in Hemodialysis Patients: A 2-Year Cohort Study from the Annual Survey of the Japanese Renal Data Registry. American Journal of Nephrology, 2017, 46, 82-92.	1.4	32
23	Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients. American Journal of Nephrology, 2018, 47, 406-414.	1.4	32
24	Effects of Levocarnitine on Brachial-Ankle Pulse Wave Velocity in Hemodialysis Patients: A Randomized Controlled Trial. Nutrients, 2014, 6, 5992-6004.	1.7	31
25	Glycated albumin versus hemoglobin A1c and mortality in diabetic hemodialysis patients: a cohort study. Nephrology Dialysis Transplantation, 2018, 33, 1150-1158.	0.4	29
26	Is there a "burnt-out diabetes―phenomenon in patients on hemodialysis?. Diabetes Research and Clinical Practice, 2017, 130, 211-220.	1.1	27
27	Combination therapy with mitiglinide and voglibose improves glycemic control in type 2 diabetic patients on hemodialysis. Expert Opinion on Pharmacotherapy, 2010, 11, 169-176.	0.9	26
28	Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertension Research, 2011, 34, 935-941.	1.5	26
29	Taurine and magnesium supplementation enhances the function of endothelial progenitor cells through antioxidation in healthy men and spontaneously hypertensive rats. Hypertension Research, 2016, 39, 848-856.	1.5	26
30	Scoring system for the diagnosis of bilateral primary aldosteronism in the outpatient setting before adrenal venous sampling. Clinical Endocrinology, 2017, 86, 467-472.	1.2	26
31	Annual dialysis data report 2018, JSDT Renal Data Registry: dialysis fluid quality, hemodialysis and hemodiafiltration, peritoneal dialysis, and diabetes. Renal Replacement Therapy, 2020, 6, .	0.3	26
32	Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 159-164.	1.0	25
33	Comparison of Sustained Hemodiafiltration with Acetate-Free Dialysate and Continuous Venovenous Hemodiafiltration for the Treatment of Critically III Patients with Acute Kidney Injury. International Journal of Nephrology, 2011, 2011, 1-8.	0.7	24
34	Involvement of complement 3 in the salt-sensitive hypertension by activation of renal renin-angiotensin system in spontaneously hypertensive rats. American Journal of Physiology - Renal Physiology, 2018, 315, F1747-F1758.	1.3	22
35	A Case Report of Acute Renal Failure and Fulminant Hepatitis Associated With Edaravone Administration in a Cerebral Infarction Patient. Therapeutic Apheresis and Dialysis, 2007, 11, 235-240.	0.4	21
36	Clinical effectiveness and safety evaluation of long-term pioglitazone treatment for erythropoietin responsiveness and insulin resistance in type 2 diabetic patients on hemodialysis. Expert Opinion on Pharmacotherapy, 2010, 11, 1611-1620.	0.9	21

#	Article	IF	CITATIONS
37	Glycemic control and survival in peritoneal dialysis patients with diabetes: A 2-year nationwide cohort study. Scientific Reports, 2019, 9, 3320.	1.6	21
38	DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice. Contributions To Nephrology, 2015, 185, 98-115.	1.1	20
39	Glycated Albumin versus Glycated Hemoglobin as a Glycemic Indicator in Diabetic Patients on Peritoneal Dialysis. International Journal of Molecular Sciences, 2016, 17, 619.	1.8	20
40	Effects of a spleen tyrosine kinase inhibitor on progression of the lupus nephritis in mice. Journal of Pharmacological Sciences, 2017, 134, 29-36.	1.1	20
41	Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease. Endocrine Journal, 2011, 58, 663-674.	0.7	19
42	L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. Heart and Vessels, 2013, 28, 480-489.	0.5	19
43	Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study. Diabetes Technology and Therapeutics, 2018, 20, 681-688.	2.4	19
44	Efficacy of L-carnitine supplementation for improving lean body mass and physical function in patients on hemodialysis: a randomized controlled trial. European Journal of Clinical Nutrition, 2019, 73, 293-301.	1.3	19
45	Predictors of outcomes in patients on peritoneal dialysis: A 2-year nationwide cohort study. Scientific Reports, 2019, 9, 3967.	1.6	18
46	Contribution of TGF-β1 and Effects of Gene Silencer Pyrrole-Imidazole Polyamides Targeting TGF-β1 in Diabetic Nephropathy. Molecules, 2020, 25, 950.	1.7	18
47	Isolated ACTH deficiency during single-agent pembrolizumab for squamous cell lung carcinoma: a case report. Clinical Diabetes and Endocrinology, 2020, 6, 1.	1.3	18
48	Plasma insulin and C-peptide concentrations in diabetic patients undergoing hemodialysis: Comparison with five types of high-flux dialyzer membranes. Diabetes Research and Clinical Practice, 2008, 82, e17-e19.	1.1	16
49	Additive renoprotective effects of aliskiren on angiotensin receptor blocker and calcium channel blocker treatments for type 2 diabetic patients with albuminuria. Hypertension Research, 2012, 35, 874-881.	1.5	16
50	Levocarnitine Injections Decrease the Need for Erythropoiesis-Stimulating Agents in Hemodialysis Patients with Renal Anemia. CardioRenal Medicine, 2017, 7, 188-197.	0.7	16
51	Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endocrine Journal, 2010, 57, 579-586.	0.7	15
52	Prevalence of Carnitine Deficiency and Decreased Carnitine Levels in Patients on Hemodialysis. Blood Purification, 2019, 47, 38-44.	0.9	15
53	Prevalence of Zinc Deficiency in Japanese Patients on Peritoneal Dialysis: Comparative Study in Patients on Hemodialysis. Nutrients, 2020, 12, 764.	1.7	15
54	Assessment of the accuracy of an intermittentâ€scanning continuous glucose monitoring device in patients with type 2 diabetes mellitus undergoing hemodialysis (<scp>AIDT2H</scp>) study. Therapeutic Apheresis and Dialysis, 2021, 25, 586-594.	0.4	15

#	Article	IF	CITATIONS
55	Comparison between the antiproteinuric effects of the calcium channel blockers benidipine and cilnidipine in combination with angiotensin receptor blockers in hypertensive patients with chronic kidney disease. Expert Opinion on Investigational Drugs, 2010, 19, 1027-1037.	1.9	14
56	The adrenal gland circadian clock exhibits a distinct phase advance in spontaneously hypertensive rats. Hypertension Research, 2019, 42, 165-173.	1.5	14
57	Significance of Levocarnitine Treatment in Dialysis Patients. Nutrients, 2021, 13, 1219.	1.7	14
58	Efficacy of pioglitazone on type 2 diabetic patients with hemodialysis. Diabetes Research and Clinical Practice, 2008, 80, 432-438.	1.1	13
59	Systematic implantation of dedifferentiated fat cells ameliorated monoclonal antibody 1-22-3-induced glomerulonephritis by immunosuppression with increases in TNF-stimulated gene 6. Stem Cell Research and Therapy, 2015, 6, 80.	2.4	13
60	Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial. Diabetes Research and Clinical Practice, 2016, 116, 244-252.	1.1	13
61	Subtype prediction in primary aldosteronism: measurement of circadian variation of adrenocortical hormones and 24â€h urinary aldosterone. Clinical Endocrinology, 2016, 84, 814-821.	1.2	13
62	Application of explainable ensemble artificial intelligence model to categorization of hemodialysis-patient and treatment using nationwide-real-world data in Japan. PLoS ONE, 2020, 15, e0233491.	1.1	13
63	Comparison of Clinical Trajectories before Initiation of Renal Replacement Therapy between Diabetic Nephropathy and Nephrosclerosis on the KDIGO Guidelines Heat Map. Journal of Diabetes Research, 2016, 2016, 1-9.	1.0	12
64	Role of complement 3 in the pathogenesis of hypertension. Hypertension Research, 2020, 43, 255-262.	1.5	12
65	Combination of once-weekly haemodialysis with peritoneal dialysis is associated with lower mortality compared with peritoneal dialysis alone: a longitudinal study. CKJ: Clinical Kidney Journal, 2021, 14, 1610-1617.	1.4	12
66	Antiproteinuric and Blood Pressure–Lowering Effects of a Fixed-Dose Combination of Losartan and Hydrochlorothiazide in Hypertensive Patients with Stage 3 Chronic Kidney Disease. Pharmacotherapy, 2009, 29, 1061-1072.	1.2	11
67	Unusual Manifestation of Graves' Disease: Ventricular Fibrillation. European Thyroid Journal, 2015, 4, 207-212.	1.2	11
68	Prevalence of Carnitine Deficiency and Decreased Carnitine Levels in Patients on Peritoneal Dialysis. Nutrients, 2019, 11, 2645.	1.7	11
69	Visualization of Blood Glucose Fluctuations Using Continuous Glucose Monitoring in Patients Undergoing Hemodialysis. Journal of Diabetes Science and Technology, 2019, 13, 413-414.	1.3	11
70	Super high-flux membrane dialyzers improve mortality in patients on hemodialysis: a 3-year nationwide cohort study. CKJ: Clinical Kidney Journal, 2022, 15, 473-483.	1.4	11
71	Effect of cosyntropin during adrenal venous sampling on subtype of primary aldosteronism: analysis of surgical outcome. European Journal of Endocrinology, 2020, 182, 265-273.	1.9	11
72	Efficacy and Safety of Pregabalin for the Treatment of Neuropathic Pain in Patients Undergoing Hemodialysis. Clinical Drug Investigation, 2017, 37, 95-102.	1.1	10

#	Article	IF	CITATIONS
73	Preclinical Study of DNA-Recognized Peptide Compound Pyrrole-Imidazole Polyamide Targeting Human TGF-β1 Promoter for Progressive Renal Diseases in the Common Marmoset. Molecules, 2019, 24, 3178.	1.7	10
74	Role of complement 3 in renin generation during the differentiation of mesenchymal stem cells to smooth muscle cells. American Journal of Physiology - Cell Physiology, 2020, 318, C981-C990.	2.1	10
75	Urinary ACE2 is associated with urinary L-FABP and albuminuria in patients with chronic kidney disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 421-427.	0.6	9
76	Glycated albumin and hemoglobin A1c levels and cause-specific mortality by patients' conditions among hemodialysis patients with diabetes: a 3-year nationwide cohort study. BMJ Open Diabetes Research and Care, 2020, 8, e001642.	1.2	9
77	Clinical Evaluation of Pneumoniaâ€associated Rhabdomyolysis With Acute Renal Failure. Therapeutic Apheresis and Dialysis, 2008, 12, 171-175.	0.4	8
78	Multifunctional L/N- and L/T-type calcium channel blockers for kidney protection. Hypertension Research, 2015, 38, 804-806.	1.5	8
79	Effect of Sucroferric Oxyhydroxide on Fibroblast Growth Factor 23 Levels in Hemodialysis Patients. Nephron, 2018, 140, 161-168.	0.9	8
80	Mobility performance among healthy older adults eligible for long-term care in Japan: a prospective observational study. Aging Clinical and Experimental Research, 2020, 32, 1931-1937.	1.4	8
81	Adrenal Venous Sampling for Subtype Diagnosis of Primary Hyperaldosteronism. Endocrinology and Metabolism, 2021, 36, 965-973.	1.3	8
82	Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease. Heart and Vessels, 2013, 28, 442-452.	0.5	7
83	Rate of the "burnt-out diabetes―phenomenon in patients on peritoneal dialysis. Diabetes Research and Clinical Practice, 2018, 143, 254-262.	1.1	7
84	Seasonal variation in hydration status among communityâ€dwelling elderly in Japan. Geriatrics and Gerontology International, 2020, 20, 904-910.	0.7	7
85	Association between plasma aldosterone and markers of tubular and glomerular damage in primary aldosteronism. Clinical Endocrinology, 2021, 94, 920-926.	1.2	7
86	Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage. International Journal of Molecular Sciences, 2015, 16, 30181-30189.	1.8	6
87	Marked alteration of glycemic profile surrounding lanreotide administration in acromegaly: A case report. Journal of Diabetes Investigation, 2018, 9, 223-225.	1.1	6
88	Dialyzer Classification and Mortality in Hemodialysis Patients: A 3-Year Nationwide Cohort Study. Frontiers in Medicine, 2021, 8, 740461.	1.2	6
89	Mobility performance impacts mortality risk in community-dwelling healthy older adults in Japan: a prospective observational study. Aging Clinical and Experimental Research, 2021, 33, 2511-2517.	1.4	6
90	Increased expression of acyl-CoA oxidase 2 in the kidney with plasma phytanic acid and altered gut microbiota in spontaneously hypertensive rats. Hypertension Research, 2021, 44, 651-661.	1.5	6

#	Article	IF	CITATIONS
91	Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 1285-1303.	1.5	5
92	International Normalized Ratio Decreases After Hemodialysis Treatment in Patients Treated With Warfarin. Journal of Cardiovascular Pharmacology, 2012, 60, 502-507.	0.8	5
93	A Trial of Pitavastatin Versus Rosuvastatin for Dyslipidemia in Chronic Kidney Disease. Journal of Atherosclerosis and Thrombosis, 2015, 22, 1235-1247.	0.9	5
94	A case of apolipoprotein A-I deficiency due to carboxyl-terminal truncation. Journal of Clinical Lipidology, 2018, 12, 511-514.	0.6	5
95	Effects of Levocarnitine Treatment on the Cardiac Function in Hemodialysis Patients. Internal Medicine, 2018, 57, 3503-3505.	0.3	5
96	Acute esophageal necrosis after cellulitis in an obese patient with diabetes mellitus. Journal of Diabetes Investigation, 2020, 11, 250-252.	1.1	5
97	Hyponatremia Associated with Prophylactic Low-Dose Trimethoprim during Systemic Corticosteroid Therapy for AQP4-Positive Optic Neuritis in a Diabetic Patient. Antibiotics, 2020, 9, 201.	1.5	5
98	Effects of LDL apheresis on proteinuria in patients with diabetes mellitus, severe proteinuria, and dyslipidemia. Clinical and Experimental Nephrology, 2021, 25, 1-8.	0.7	5
99	Primary aldosteronism and obstructive sleep apnea. Medicine (United States), 2021, 100, e25049.	0.4	5
100	Identification of Clock Genes Related to Hypertension in Kidney From Spontaneously Hypertensive Rats. American Journal of Hypertension, 2020, 33, 1136-1145.	1.0	5
101	Octreotide for hypoglycemia caused by sulfonylurea and DPP-4 inhibitor. Diabetes Research and Clinical Practice, 2015, 109, e8-e10.	1.1	4
102	High-performance dialyzers and mortality in maintenance hemodialysis patients. Scientific Reports, 2021, 11, 12272.	1.6	4
103	Dialyzer surface area is a significant predictor of mortality in patients on hemodialysis: a 3-year nationwide cohort study. Scientific Reports, 2021, 11, 20616.	1.6	4
104	A case of femoral hemorrhage in a patient with microscopic polyangiitis with low levels of myeloperoxidase-antineutrophil cytoplasmic autoantibody. Clinical and Experimental Nephrology, 2011, 15, 414-418.	0.7	3
105	Plasma <scp>adrenocorticotropic hormone</scp> but not aldosterone is correlated with blood pressure in patients with aldosteroneâ€producing adenomas. Journal of Clinical Hypertension, 2017, 19, 280-286.	1.0	3
106	Correlation between Aortic Calcification Score and Biochemical Parameters in Hemodialysis Patients. Contributions To Nephrology, 2019, 198, 40-51.	1.1	3
107	<p>Retention of aberrant cortisol secretion in a patient with bilateral macronodular adrenal hyperplasia after unilateral adrenalectomy</p> . Therapeutics and Clinical Risk Management, 2019, Volume 15, 337-342.	0.9	3
108	Blood pressure targets and pharmacotherapy for hypertensive patients on hemodialysis. Expert Opinion on Pharmacotherapy, 2020, 21, 1219-1240.	0.9	3

#	Article	IF	CITATIONS
109	Transcriptional Suppression of Diabetic Nephropathy with Novel Gene Silencer Pyrrole-Imidazole Polyamides Preventing USF1 Binding to the TGF-β1 Promoter. International Journal of Molecular Sciences, 2021, 22, 4741.	1.8	3
110	Inverse Correlation Between Grip Strength and Serum Phosphorus: A Retrospective Observational Study in Japanese Elderly with Poorly Controlled Type 2 Diabetes. Geriatrics (Switzerland), 2020, 5, 33.	0.6	3
111	Lipoprotein Lipase Deficiency Arising in Type V Dyslipidemia. Internal Medicine, 2019, 58, 251-257.	0.3	2
112	Adiponectin Receptor gene Polymorphisms are Associated with Kidney Function in Elderly Japanese Populations. Journal of Atherosclerosis and Thrombosis, 2019, 26, 328-339.	0.9	2
113	Calculation of expected remaining lifetime of dialysis patients in Japan. Renal Replacement Therapy, 2020, 6, .	0.3	2
114	A Single Episode of Hypoglycemia as a Possible Early Warning Sign of Adrenal Insufficiency. Therapeutics and Clinical Risk Management, 2020, Volume 16, 147-153.	0.9	2
115	TWIST1 transcriptionally upregulates complement 3 in glomerular mesangial cells from spontaneously hypertensive rats. Hypertension Research, 2021, , .	1.5	2
116	SP379EFFICACY AND SAFETY OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR IN HEMODIALYSIS PATIENTS WITH TYPE 2 DIABETES. Nephrology Dialysis Transplantation, 2016, 31, i216-i216.	0.4	1
117	Rationale and study design of a clinical trial to assess the effects of LDL apheresis on proteinuria in diabetic patients with severe proteinuria and dyslipidemia. Clinical and Experimental Nephrology, 2018, 22, 591-596.	0.7	1
118	Effect of Adult Weight Gain on Non-Alcoholic Fatty Liver Disease and Its Association with Anthropometric Parameters in the Lean Japanese Population. Diagnostics, 2020, 10, 863.	1.3	1
119	Association between the use of exchange devices for peritoneal dialysis fluids and peritonitis incidence: A nationwide cohort study. Peritoneal Dialysis International, 2021, , 089686082110515.	1.1	1
120	FP655EFFECTS OF DIALYZER MEMBRANE MATERIALS ON SURVIVAL IN CHRONIC HEMODIALYSIS PATIENTS: A 2-YEAR COHORT STUDY FROM THE ANNUAL SURVEY OF THE JAPANESE RENAL DATA REGISTRY. Nephrology Dialysis Transplantation, 2018, 33, i265-i265.	0.4	0
121	FP716EFFICACY OF LEVOCARNITINE SUPPLEMENTATION IN IMPROVING LEAN BODY MASS AND PHYSICAL FUNCTION IN PATIENTS ON HEMODIALYSIS: A RANDOMIZED CONTROLLED TRIAL. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
122	Method of Determining Pyrrole–Imidazole Polyamide in Rat Plasma Using Ultra-Fast Liquid Chromatography-Ultraviolet Spectrometry. Biological and Pharmaceutical Bulletin, 2020, 43, 124-128.	0.6	0
123	Tuberculosis Relapse in the Epididymis After the Completion of Nine Months of Anti-Tuberculosis Chemotherapy in a Patient with Poorly Controlled Diabetes Mellitus. Therapeutics and Clinical Risk Management, 2021, Volume 17, 463-470.	0.9	0
124	The clinical efficacy of maxacalcitol for secondary hyperparathyroidism in hemodialysis patients: response of whole-PTH and biochemical bone markers. Nihon Toseki Igakkai Zasshi, 2003, 36, 1423-1429.	0.2	0
125	9. ç³–å°¿ç— (DM). Nihon Toseki Igakkai Zasshi, 2019, 52, 781-787.	0.2	0
126	Diet Therapy for Chronic Kidney Disease. Journal of the Nihon University Medical Association, 2019, 78, 237-241.	0.0	0

#	Article	IF	CITATIONS
127	MON-198 Cosyntropin Stimulation on Adrenal Venous Sampling Obscure Surgically Curable Primary Aldosteronism. Journal of the Endocrine Society, 2020, 4, .	0.1	0
128	Title is missing!. , 2020, 15, e0233491.		0
129	Title is missing!. , 2020, 15, e0233491.		0
130	Title is missing!. , 2020, 15, e0233491.		0
131	Title is missing!. , 2020, 15, e0233491.		0